November 12, 2026

To, The Department of Corporate Services, **BSE Limited,** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001 **Scrip Code – 544709**	To, The Listing Department, **National Stock Exchange of India Limited,** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 **Symbol – GAUDIUMIVF**
ISIN: INE0P8B01020	**ISIN:** INE0P8B01020

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on November 12, 2026.

Ref: Disclosures pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors ("Board") of Gaudium IVF and Women Health Limited ("Company"), at its meeting held on November 12, 2026 i.e. today has, inter alia, considered and approved the following matters:

1. Approved the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2026 ("Unaudited Financial Results"). The copy of the Unaudited Financial Results along with the Limited Review Report received from the Statutory Auditors, M/s. S K G N & Associates LLP, Chartered Accountants, is enclosed herewith as **'Annexure A'**.

2. Appointment of Dr. Ravish Manchanda as National Head – Operations Expansion & Strategy with effect from November 12, 2026, and designated him as Senior Management Personnel ("SMP") of the Company.

Details as required under Regulation 30 of the Listing Regulations and the SEBI Circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time are provided in **'Annexure B'**.

3. Based on the recommendation of the Audit Committee, the Board has approved a variation in the objects of the Initial Public Offer ("IPO") as stated in the Prospectus dated February 25, 2026, in respect of Object No. 1 – establishment of 19 New IVF Centres, involving (i) change / substitution of 6 cities / locations; and (ii) revision of the schedule of establishment, with all 19 centres to be established by Fiscal 2029 ("Proposed Variation"), subject to the approval of the Members by way of a Special Resolution through Postal Ballot.

There is no change in the amount of ₹5,000.00 Lakhs allocated to the said object. The details of the Proposed Variation are enclosed as **'Annexure C'**.

4. The statement of Deviation(s) or Variation(s), pursuant to Regulation 32 of the SEBI Listing Regulations read with SEBI Master circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the utilization of funds raised through Initial Public Offer ("IPO") for the quarter ended September 30, 2026, is enclosed herewith as **'Annexure D'.**

5. The Board of Directors has approved the draft Postal ballot notice for approval of shareholders for a Proposed Variation regarding 19 New IVF Centres specifically the substitution of 6 locations and revision of the schedule and manner of establishment.

Postal Ballot Notice shall be sent to the shareholders in due course and the same shall be filed with the stock exchanges.

6. Amendment to the Policy on Code of practices and procedures for fair disclosure of unpublished price sensitive information, in accordance with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time.

The amended policy will be made available on the website of the Company at https://www.gaudiumivfcentre.com/assets/fornt/images/pdf/corporatepolicies/Code%20for%20Fair%20Disclosure.pdf

This disclosure will also be hosted on the website of the Company at www.gaudiumivfcentre.com

We request you to please take the same on record and arrange to bring this to the notice of all concerned.

The Board meeting commenced at 03:30 P.M. and concluded at 06:45 P.M.

Thanking you,
Yours faithfully.

For and on behalf of Gaudium IVF and Women Health Limited

NAVEEN KUMAR
Digitally signed by NAVEEN KUMAR
Date: 2026.11.12 20:20:40 +05'30'

Naveen Kumar
Company Secretary and Compliance Officer
Membership No: A69788

Encl.: a/a

Annexure-A

Independent Auditor's Review Report on the Unaudited Standalone Financial Results for the Quarter and Six Months Ended September 30, 2026 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gaudium IVF and Women Health Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Gaudium IVF and Women Health Limited (the "Company") for the three and six months ended 30th September 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting

SKGN & ASSOCIATES LLP * CHARTERED ACCOUNTANTS *

Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We have not reviewed the accompanying financial results and other financial information for the quarter ended Sept 30, 2025 which has been presented solely based on the information compiled by the management.

   Our conclusion on the Statement is not modified in respect of the above matter.

For S K G N & Associates LLP
Chartered Accountants
Firm registration number: 023403N/N500052

Sumit Kumar Goyal
Partner
Membership No: 515406
UDIN: 26515406CPTPXL2041
Place: New Delhi
Date: 12-11-2026

Gaudium IVF and Women Health Limited
CIN : L85100DL2015PLC278296
Registered address: B1/51, Janakpuri , New Delhi, India - 110058.
Statement of Standalone Financial Results for the three months ended September 30, 2026

Particulars	For the Quarter ended September 30, 2026	For the Quarter ended June 30, 2026	For the Quarter ended September 30, 2025	For the Half Year ended September 30, 2026	For the Half Year ended September 30, 2025	For the year ended March 31, 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited
Income						
Revenue from operations	2,805.68	1,367.73	2,294.58	4,173.41	3,521.90	7,157.85
Other income	108.48	112.36	11.85	220.84	21.85	49.81
Total income	**2,914.16**	**1,480.09**	**2,306.43**	**4,394.25**	**3,543.75**	**7,207.66**
Expenses						
Cost of rendering services	607.70	105.92	229.09	713.62	397.64	844.60
Purchase of drugs and medical consumables	103.75	92.35	112.74	196.10	230.81	450.20
Changes in inventories of drugs and medical consumables	(2.01)	28.28	21.13	26.27	(6.47)	24.60
Employee benefit expenses	193.01	220.67	188.97	413.68	362.49	772.43
Finance costs	45.31	32.26	50.68	77.57	100.31	336.19
Depreciation and amortisation expenses	136.73	67.54	58.70	204.27	136.15	243.66
Other expenses	730.39	703.11	415.00	1,433.50	790.21	1,609.43
Total expenses	**1,814.88**	**1,250.13**	**1,076.31**	**3,065.01**	**2,011.14**	**4,281.11**
Profit before tax	**1,099.28**	**229.96**	**1,230.12**	**1,329.24**	**1,532.61**	**2,926.55**
Tax expenses						
Current tax	241.49	61.54	326.53	303.04	391.98	728.87
Taxes for prior years	-	-		-		(24.62)
Deferred tax	37.82	2.07	1.05	39.89	3.39	(6.48)
Total tax expenses	**279.31**	**63.61**	**327.58**	**342.93**	**395.38**	**697.78**
Profit for the Period/year	**819.97**	**166.35**	**902.54**	**986.31**	**1,137.23**	**2,228.77**
Other Comprehensive Income (OCI)						
Items that will not be reclassified to the Statement of Profit and Loss	3.22	3.22	2.58	6.44	5.16	10.13
Income tax relating to items that will not be reclassified to Statement of Profit and Loss	(0.81)	(0.81)	(0.65)	(1.62)	(1.31)	(2.55)
Other Comprehensive Income for the period/year, net of tax	**2.41**	**2.41**	**1.93**	**4.82**	**3.85**	**7.58**
Total comprehensive income for the Period/year	**822.38**	**168.76**	**904.47**	**991.12**	**1,141.08**	**2,236.34**
Paid-up equity share capital (Face value Rs.5/- per share)	3,639.34	3,639.34	3,069.72	3,639.34	3,069.72	3,639.34
Other Equity						11,287.14
Earning per equity share (EPS) (par value of ₹ 5)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic and Diluted (in absolute rupees)	1.13	0.23	1.47	1.36	1.85	3.59

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

Gaudium IVF and Women Health Limited
CIN : L85100DL2015PLC278296
Registered address: B1/51, Janakpuri , New Delhi, India - 110058.
Statement of Unaudited Standalone Balance Sheet as at September 30, 2026

Particulars	As at September 30, 2026	As at March 31, 2026
Assets		
Non-current assets		
Property, plant and equipment	716.75	534.67
Right of use asset	2,050.89	121.62
Goodwill	13.82	13.82
Other intangible assets	2,241.37	865.28
Intangible assets under development	-	1,196.83
Financial assets:		
Investments	625.00	625.00
Loans	400.00	400.00
Other financial assets	4,135.23	8,113.08
Other non-current assets	2,234.23	-
Total non-current assets	**12,417.29**	**11,870.30**
Current assets		
Inventories	203.59	229.86
Financial assets:		
Trade receivables	3,283.39	4,260.42
Cash and cash equivalents	2,020.45	853.69
Other financial assets	222.94	520.86
Other current assets	272.31	123.46
Total current assets	**6,002.68**	**5,988.29**
Total assets	**18,419.97**	**17,858.59**
Equity and liabilities		
Equity		
Equity share capital	3,639.34	3,639.34
Other equity	12,262.05	11,287.14
Total equity	**15,901.39**	**14,926.48**
Non-current liabilities		
Financial liabilities:		
Lease liabilities	1,529.10	128.26
Provisions	39.30	39.86
Deferred tax liabilities (net)	95.67	55.77
Total non-current liabilities	**1,664.07**	**223.89**
Current liabilities		
Financial liabilities		
Borrowings	-	2,109.95
Lease liabilities	260.44	21.28
Trade payables		
- total outstanding dues of micro and small enterprises	20.53	45.85
- total outstanding dues other than micro and small enterprises	102.86	237.40
Other financial liabilities	69.58	77.20
Other current liabilities	33.81	81.94
Provisions	16.23	9.93
Current tax liabilities (net)	351.06	124.67
Total current liabilities	**854.51**	**2,708.22**
Total liabilities	**2,518.58**	**2,932.11**
Total equity and liabilities	**18,419.97**	**17,858.59**

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

Gaudium IVF and Women Health Limited
CIN : L85100DL2015PLC278296
Registered address: B1/51, Janakpuri , New Delhi, India - 110058.
Statement of Unaudited Standalone Cash Flows for the half year ended September 30, 2026

Particulars	For the half year ended 30th September 2026	For the half year ended 30th September 2025
Cash flows from operating activities		
Profit before tax for the period	1,329.24	1,537.77
Adjustments for non-cash items:		
Depreciation expenses	204.27	136.15
Finance costs	77.57	100.31
Allowance on Expected credit loss	18.42	14.90
Unclaimed balances and excess provisions written back	(1.31)	(1.85)
Interest income	(219.53)	(20.00)
Remeasurement gains on defined benefit plans (OCI)	6.45	(5.16)
Operating cash flow before working capital changes	**1,415.11**	**1,762.12**
Movement in working capital:		
Adjustments for (increase)/decrease in assets:		
(Increase)/Decrease in other financial assets	266.40	81.99
(Increase) in trade receivables	958.61	(1,573.53)
(Increase)/Decrease in inventories	26.27	(6.47)
(Increase)/Decrease in other current assets	(148.85)	67.03
Adjustments for increase/ (decrease) in liabilities:		
Increase in trade payables	(159.84)	6.17
Increase in other financial liabilities	2.05	-
Increase in provisions	7.06	7.48
Increase in other current liabilities	(48.13)	16.88
Cash flow generated from operating activities	**2,318.68**	**361.67**
Income tax (net of refunds)	(78.26)	(191.99)
Net cash flow generated from operating activities	**2,240.42**	**169.68**
Cash flows from investing activities		
Purchase of property, plant and equipment and intangible assets	(485.47)	(467.03)
Capital advances paid	(2,234.23)	-
Investment in 0% unsecured optionally convertible debentures	-	1.00
Bank Deposits	4,028.13	-
Interest income	200.75	20.00
Net cash flow used in investing activities	**1,509.18**	**(446.03)**
Share issue expense paid	(16.24)	-
Interest paid on lease liabilities	(50.40)	-
Proceeds from borrowings	-	357.20
Proceeds from/ (repayment of) short term borrowings (net)	(2,109.95)	-
Repayment of lease liabilities (principal)	(369.42)	(8.69)
Interest paid on statutory dues	(0.40)	-
Interest and processing fees paid on borrowings	(36.43)	(100.31)
Net cash flow generated from financing activities	**(2,582.84)**	**248.20**
Net increase/ (decrease) in cash and cash equivalents	**1,166.76**	**(28.15)**
Cash and cash equivalents at the beginning of the period	853.69	686.67
Cash and cash equivalents at the end of the period	**2,020.45**	**658.52**
Cash and cash equivalents comprise of :		
Bank balances, unrestricted	1,583.70	17.99
Cash on hand	436.75	640.53
Cash and cash equivalents at the end of the period	**2,020.45**	**658.52**

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

gaudium IVF
Delivering Motherhood Dreams

NOTES TO THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2026

(₹ in lakhs, unless otherwise stated)

1. The unaudited standalone financial results of Gaudium IVF and Women Health Limited ("the Company") have been prepared in accordance with the Indian Accounting Standard, prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The above results, together with the Statement of Assets and Liabilities as at 30 September 2026 and the Statement of Cash Flows for the half-year ended on that date, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 November 2026. The Statutory Auditors of the Company, S K G N & Associates LLP, Chartered Accountants (FRN: 023403N/N500052), have carried out a limited review of the said results in terms of Regulation 33 of the Listing Regulations and have expressed an unmodified conclusion thereon.

3. The equity shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 27 February 2026. Accordingly, the figures for the quarter ended 30 September 2025 have been approved by the Board of Directors but have not been subjected to limited review by the Statutory Auditors. The figures for the half-year ended 30 September 2025 are as audited for the purposes of the Offer Document. Management has exercised necessary due diligence to ensure that such comparative figures present a true and fair view of the affairs of the Company.

4. The Company is engaged in a single business segment, namely "Health Care Business" as per Ind AS 108 "Operating Segments".

5. Upon commencement of the new centres, the Company has recognised right-of-use assets and corresponding lease liabilities in accordance with Ind AS 116 "Leases". Consequently, right-of-use assets have increased from ₹121.62 lakhs as at 31 March 2026 to ₹2,050.89 lakhs as at 30 September 2026, and lease liabilities (current and non-current) have increased from ₹149.54 lakhs to ₹1,789.54 lakhs over the same period.

6. Items of expenditure which exceed 10% of total expenditure are as given below: - *(₹ in lakhs)*

Particulars	For the Quarter ended September 30, 2026	For the Quarter ended June 30, 2026	For the Quarter ended September 30, 2025	For the Half Year ended September 30, 2026	For the Half Year ended September 30, 2025	For the year ended March 31, 2026
Sales and marketing expenses	361.46	382.96	126.72	744.42	314.72	672.97
Rent	38.5	63.12	58.31	101.62	114.80	231.76
Legal and professional fees	148.43	146.36	43.85	295.19	126.49	265.83

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

7. During the financial year ended 31 March 2026, the Company completed its Initial Public Offer ("IPO") of 2,08,86,200 equity shares of face value ₹5 each at an issue price of ₹79 per equity share (including a share premium of ₹74 per equity share), comprising a fresh issue of 1,13,92,500 equity shares aggregating ₹9,000.08 lakhs and an offer for sale of 94,93,700 equity shares by the selling shareholder aggregating ₹7,500.02 lakhs. Share issue expenses attributable to the fresh issue have been adjusted against the Securities Premium in accordance with Section 52 of the Act.

The utilisation of the gross proceeds of ₹9,000.08 lakhs from the fresh issue of equity shares under the IPO, as certified by the Statutory Auditors of the Company, is summarised below:

(₹ in lakhs)

Sr. No.	Objects of the issue	Amount as per Offer Document	Revised cost	Amount utilised up to 30.06.2026	Amount utilised during quarter ended 30.09.2026	Cumulative amount utilised up to 30.09.2026	Unutilised amount as at 30.09.2026
1	Funding capital expenditure towards establishment of new IVF centres	5,000.00	No revision	102.95	1,245.53	1,348.48	3,651.52
2	Repayment / prepayment, in full or in part, of certain outstanding loans availed by the Company;	2,000.00	1,807.37	1,807.37	Nil	1,807.37	Nil
3	General corporate purposes	1,228.19	1,420.82	721.02	416.44	1,137.46	283.37
	Sub-total (A)	**8,228.19**	-	**2,631.34**	**1,661.97**	**4,293.31**	**3,934.89**
4	Fresh issue related expenses (B)	771.89	-	771.89	-	771.89	-
	Total (A + B)	**9,000.08**	-	**3,403.23**	**1,661.97**	**5,065.20**	**3,934.89**
	Add: Interest earned on fixed deposits (net of tax)	–	–	–	–	–	*53.15*
	Total unutilised proceeds as at 30.09.2026						**3,988.04**

- The proceeds have been utilised for the purposes for which they were raised, as stated in the Offer Document.
- The unutilised proceeds as at 30 September 2026, aggregating ₹3,988.04 lakhs (including net interest of ₹53.15 lakhs earned on fixed deposits, after deduction of applicable taxes), are held as under:

Name of the bank	Nature of deposit / account	Amount (₹ in lakhs)
HDFC Bank Limited	Fixed deposit	1,250.00
HDFC Bank Limited	Fixed deposit	2,700.00
HDFC Bank Limited	Current account	29.4
Axis Bank Limited – IPO Public Offer Account	Current account	8.64
Total		**3,988.04**

8. Other income net includes interest on fixed deposit amounting to Rs. 97.29 lakhs for the quarter ended 30 September 2026 (30 September 2025: interest on fixed deposit is nil, year ended 31 March 2026: interest on fixed deposit of Rs. 7.96 lakhs).

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

gaudium IVF
Delivering Motherhood Dreams

9. Previous period figures have been regrouped and/or reclassified wherever necessary to conform to the classification of the current period.

10. The Financial Results for the quarter ended 30th September, 2026 is the balancing figure between the Limited Reviewed Unaudited Results for the half year ended 30th September, 2026 and the Limited Reviewed Unaudited Results up to the first quarter of the Financial Year 2026-27.

11. The above results are available on the website of the Company (www.gaudiumivfcentre.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of the Board of Directors of
Gaudium IVF and Women Health Limited

Dr. Manika Khanna
Chairperson and Managing Director
DIN: 07090907

Gaudium IVF and Women Health Limited
New Delhi

SKGN ASSOCIATES LLP
For Identification Only
CHARTERED ACCOUNTANTS

Place: New Delhi
Date: November 12, 2026

Independent Auditor's Review Report on the Unaudited Consolidated Financial Results for the Quarter and Six Months Ended September 30, 2026 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gaudium IVF and Women Health Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Gaudium IVF and Women Health Limited (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), for the three and six months ended 30 September 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

1. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review,

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim Financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of Listing Regulations, to the extent applicable.

3. The Statement includes the results of the following entities

   (i) Holding Company:
   Gaudium IVF and Women Health Limited
   (ii) Subsidiaries:
   Gaudium International Private Limited
   EKK Global Private Limited (till August 05, 2025)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We have not reviewed the accompanying consolidated financial results and other financial information for the quarter ended September 30, 2025 which has been presented solely based on the information compiled by the management.

   Our conclusion on the Statement is not modified in respect of the above matter.

For S K G N & Associates LLP
Chartered Accountants
Firm registration number: 023403N/N500052

Sumit Kumar Goyal
Partner
Membership No: 515406
UDIN: 26515406MRSF8627
Place: New Delhi
Date: 12-11-2026

Gaudium IVF and Women Health Limited

CIN: L85100DL2015PLC278296

Registered address: B1/51, Janakpuri , New Delhi, India - 110058.

Consolidated statement of assets and liabilities as at September 30, 2026

(Rupees in Lakhs)

Particulars	As at September 30, 2026	As at March 31, 2026
	Unaudited	Audited
ASSETS		
Non-current assets		
Property, plant and equipment	922.37	746.44
Right-of-use assets	2,050.89	121.62
Goodwill	13.82	37.00
Other intangible assets	2,241.37	865.28
Intangible assets under development	-	1,196.83
Financial assets		
Investments	500.00	500.00
Loans	400.00	400.00
Other financial assets	4,135.23	8,113.08
Other non-current assets	2,234.23	-
Total non-current assets	**12,497.91**	**11,980.25**
Current assets		
Inventories	314.66	354.46
Financial assets		
Trade receivables	4,530.30	5,337.93
Cash and cash equivalents	2,048.56	878.57
Other financial assets	225.94	523.86
Other current assets	425.09	235.38
Total current assets	**7,544.55**	**7,330.20**
Total assets	**20,042.46**	**19,310.45**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,639.34	3,639.34
Other equity	12,675.20	11,590.87
Total equity	**16,314.54**	**15,230.21**
Liabilities		
Non-current liabilities		
Financial liabilities		
Lease liabilities	1,529.10	128.26
Provisions	39.30	39.86
Deferred tax liabilities (net)	101.44	59.39
Total non-current liabilities	**1,669.84**	**227.51**
Current liabilities		
Financial liabilities		
Borrowings	479.87	2,307.48
Lease liabilities	260.44	21.28
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	48.18	51.94
Total outstanding dues of creditors other than micro enterprises and small enterprises	723.35	1,170.98
Other financial liabilities	76.73	79.39
Other current liabilities	54.65	82.74
Provisions	16.23	9.93
Current tax liabilities (net)	398.62	128.99
Total current liabilities	**2,058.07**	**3,852.73**
Total liabilities	**3,727.91**	**4,080.24**
Total equity and liabilities	**20,042.46**	**19,310.45**

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

Gaudium IVF and Women Health Limited
CIN: L85100DL2015PLC278296
Registered address: B1/51, Janakpuri , New Delhi, India - 110058.
Statement of consolidated financial results for the quarter and half year ended September 30, 2026

(Rupees in Lakhs)

Particulars	Quarter ended September 30, 2026	Quarter ended June 30, 2026	Quarter ended September 30, 2025	Half year ended September 30, 2026	Half year ended September 30, 2025	For the year ended March 31, 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited
Income						
Revenue from operations	3,741.11	1,937.66	3,173.04	5,678.77	4,949.88	10,435.70
Other income	108.89	112.36	15.09	221.25	25.09	53.12
Total income	**3,850.00**	**2,050.02**	**3,188.13**	**5,900.02**	**4,974.97**	**10,488.82**
Expenses						
Cost of rendering services	607.70	105.92	229.09	713.62	397.64	844.60
Purchase of drugs and medical consumables	718.78	707.37	987.38	1,426.15	1,225.80	2,992.04
Changes in inventories of drugs and medical consumables	119.58	(79.78)	(41.23)	39.80	241.34	368.50
Employee benefit expenses	205.04	228.31	195.12	433.35	374.63	798.63
Finance costs	52.12	37.62	50.68	89.74	100.31	349.16
Depreciation and amortisation expenses	141.33	72.17	61.46	213.50	141.72	254.79
Other expenses	743.06	733.43	426.48	1,476.49	815.25	1,661.53
Total expenses	**2,587.60**	**1,805.04**	**1,908.98**	**4,392.64**	**3,296.68**	**7,269.25**
Profit before tax	**1,262.39**	**244.98**	**1,279.16**	**1,507.38**	**1,678.29**	**3,219.56**
Tax expenses						
Current tax	281.77	64.65	340.26	346.42	424.45	798.24
Taxes for prior years	-	-	-	-	-	-24.62
Deferred tax	39.31	2.74	0.99	42.05	3.28	-2.91
Total tax expenses	**321.08**	**67.39**	**341.25**	**388.47**	**427.73**	**770.72**
Profit for the Period/year	**941.31**	**177.59**	**937.91**	**1,118.91**	**1,250.56**	**2,448.85**
Profit/ (loss) before tax for the year from discontinued operation	-	-	-	-	-	(2.75)
Tax expense of discontinued operations	-	-	-	-	-	0.00
Profit/ (loss) for the period/year from discontinued operation	-	-	-	-	-	**(2.75)**
Other Comprehensive Income (OCI)						
Items that will not be reclassified to the Statement of Profit and Loss	3.22	3.22	2.58	6.44	5.16	10.13
Income tax relating to items that will not be reclassified to Statement of Profit and Loss	(0.81)	(0.81)	(0.65)	(1.62)	(1.31)	(2.55)
Other Comprehensive Income for the period/year, net of tax	**2.41**	**2.41**	**1.93**	**4.82**	**3.85**	**7.58**
Total comprehensive income for the period/year	**943.72**	**180.00**	**939.84**	**1,123.73**	**1,254.41**	**2,453.67**
Paid-up equity share capital (Face value Rs.5/- per	3,519.34	3,639.34	3,069.72	3,519.34	3,069.72	3,639.34
Other Equity						11,590.87
Earning per equity share (EPS) (par value of ₹ 5)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic and Diluted (in absolute rupees)	1.29	0.25	1.53	1.54	2.04	3.92

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

Gaudium IVF and Women Health Limited

CIN: L85100DL2015PLC278296

Registered address: B1/51, Janakpuri , New Delhi, India - 110058.

Consolidated statement of cash flows for the half year ended September 30, 2026

(Rupees in Lakhs)

Particulars	Half year ended September 30, 2026	Half year ended September 30, 2025
	Unaudited	Audited
A. Cash flow from operating activities		
Profit before tax (including discontinued operations)	1507.38	1683.45
Adjustments for:	0.00	0.00
Depreciation and amortisation expenses	213.50	141.72
Finance costs	89.74	100.31
Interest income	(219.53)	(20.00)
'Gain on Subsidiary Sale (net of exp)	0.00	(3.24)
Allowance on Expected credit loss	18.42	14.90
Unclaimed balances and excess provisions written back	(1.30)	(1.85)
Remeasurement gains on defined benefit plans (OCI)	6.45	(5.16)
Operating profit before working capital changes	**1614.66**	**1910.14**
Movement in working capital:		
(Increase)/ decrease in inventories	39.80	241.35
(Increase)/ decrease in trade receivables	828.16	(1824.73)
(Increase)/ decrease in other financial assets	266.40	82.00
(Increase)/ decrease in other current and non-current assets	(189.72)	41.92
Increase/ (decrease) in trade payables	(490.32)	(63.57)
Increase/ (decrease) in other financial liabilities	7.00	0.00
Increase/ (decrease) in other current and non-current liabilities	(28.09)	32.97
Increase/ (decrease) in provisions	7.06	7.48
Cash generated from operations	**2054.93**	**427.55**
Income tax paid (net of refunds)	(78.40)	(191.99)
Net cash flow from/ (used in) operating activities (A)	**1976.54**	**235.56**
B. Cash flow from investing activities		
Purchase of property, plant and equipment, capital work-in-progress and intangible assets	(488.53)	(567.36)
Proceeds from sale of property, plant and equipment	0.00	0.00
(Purchase)/ sale of investments (net)	0.00	0.00
(Investment in)/ redemption of bank deposits (net)	4028.13	0.00
Capital advances paid	(2234.23)	0.00
'Sale of subsidiary		3.24
Interest received	200.75	20.00
Net cash flow from/ (used in) investing activities (B)	**1506.12**	**(544.12)**
C. Cash flow from financing activities		
Proceeds from issue of equity shares (including securities premium, net of issue expenses)	(16.24)	0.00
Proceeds from/ (repayment of) non-current borrowings (net)	0.00	357.93
Proceeds from/ (repayment of) short term borrowings (net)	(1827.61)	0.00
Interest and processing fees paid on borrowings	(48.60)	(100.31)
Repayment of lease liabilities (principal)	(369.42)	(8.69)
Interest paid on lease liabilities	(50.40)	0.00
Interest paid on statutory dues	(0.40)	0.00
Net cash flow from/ (used in) financing activities (C)	**(2312.67)**	**248.92**
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	**1169.99**	**(59.63)**
Cash and cash equivalents at the beginning of the period	878.57	721.50
Cash and cash equivalents at the end of the period	**2048.56**	**661.87**

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP CHARTERED ACCOUNTANTS For Identification Only

gaudium IVF
Delivering Motherhood Dreams

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2026

(₹ in lakhs, unless otherwise stated)

1. The unaudited consolidated financial results of Gaudium IVF and Women Health Limited ("the Company") have been prepared in accordance with the Indian Accounting Standard, prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The above results, together with the Statement of Assets and Liabilities as at 30 September 2026 and the Statement of Cash Flows for the half-year ended on that date, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 November 2026. The Statutory Auditors of the Company, S K G N & Associates LLP, Chartered Accountants (FRN: 023403N/N500052), have carried out a limited review of the said results in terms of Regulation 33 of the Listing Regulations and have expressed an unmodified conclusion thereon.

3. The Group has a single business segments 'Health Care Business' as per Ind AS 108 on 'Operating Segments'.

4. During the Financial Year 2025-26, the Company completed its Initial Public Offer (IPO) of 2,08,86,200 equity shares of face value of ₹5 each at an issue price of ₹79 per share (including a share premium of ₹74 per share). The issue comprised of a fresh issue of 1,13,92,500 equity shares aggregating to ₹9,000.08 Lakhs and an offer for sale of 94,93,700 equity shares by the selling shareholder aggregating to ₹7,500.02 Lakhs. The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on February 27, 2026.

Utilization of IPO proceeds: *(₹ in Lakhs)*

Sr. No.	Objects of the issue	Amount as per Offer Document	Revised cost	Amount utilised up to 30.06.2026	Amount utilised during quarter ended 30.09.2026	Cumulative amount utilised up to 30.09.2026	Unutilised amount as at 30.09.2026
1	Funding capital expenditure towards establishment of new IVF centres	5,000.00	No revision	102.95	1,245.53	1,348.48	3,651.52
2	Repayment / prepayment, in full or in part, of certain outstanding loans availed by the Company;	2,000.00	1,807.37	1,807.37	Nil	1,807.37	Nil
3	General corporate purposes	1,228.19	1,420.82	721.02	416.44	1,137.46	283.37
	Sub-total (A)	**8,228.19**	**-**	**2,631.34**	**1,661.97**	**4,293.31**	**3,934.89**

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

Sr. No.	Objects of the issue	Amount as per Offer Document	Revised cost	Amount utilised up to 30.06.2026	Amount utilised during quarter ended 30.09.2026	Cumulative amount utilised up to 30.09.2026	Unutilised amount as at 30.09.2026
4	Fresh issue related expenses (B)	771.89	-	771.89	-	771.89	-
	Total (A + B)	**9,000.08**	**-**	**3,403.23**	**1,661.97**	**5,065.20**	**3,934.89**
	Add: Interest earned on fixed deposits (net of tax)	–	–	–	–	–	*53.15*
	Total unutilised proceeds as at 30.09.2026						**3,988.04**

- The proceeds have been utilised for the purposes for which they were raised, as stated in the Offer Document.
- The unutilised proceeds as at 30 September 2026, aggregating ₹3,988.04 lakhs (including net interest of ₹53.15 lakhs earned on fixed deposits, after deduction of applicable taxes), are held as under:

Name of the bank	Nature of deposit / account	Amount (₹ in lakhs)
HDFC Bank Limited	Fixed deposit	1,250.00
HDFC Bank Limited	Fixed deposit	2,700.00
HDFC Bank Limited	Current account	29.4
Axis Bank Limited – IPO Public Offer Account	Current account	8.64
Total		**3,988.04**

5. Items of expenditure which exceed 10% of total expenditure are as given below:-

(₹ in Lakhs)

Particulars	For the Quarter ended September 30, 2026	For the Quarter ended June 30, 2026	For the Quarter ended September 30, 2025	For the Half Year ended September 30, 2026	For the Half Year ended September 30, 2025	For the year ended March 31, 2026
Sales and marketing expenses	346.09	404.33	129.72	750.42	320.72	684.97
Rent	47.50	72.12	67.31	119.62	129.05	267.76
Legal and professional fees	148.24	146.95	43.85	295.19	126.68	266.71

Gaudium IVF and Women Health Limited New Delhi

SKGN ASSOCIATES LLP For Identification Only CHARTERED ACCOUNTANTS

gaudium IVF
Delivering Motherhood Dreams

6. Other income net includes interest on fixed deposit amounting to Rs. 97.29 lakhs for the quarter ended 30 September 2026 (30 September 2025: interest on fixed deposit is nil, year ended 31 March 2026: interest on fixed deposit of Rs. 7.96 lakhs).

7. Previous period figures have been regrouped and/or reclassified wherever necessary to conform to the classification of the current period.

8. The Financial Results for the quarter ended 30th September, 2026 is the balancing figure between the Limited Reviewed Unaudited Results for the half year ended 30th September, 2026 and the Limited Reviewed Unaudited Results up to the first quarter of the Financial Year 2026-27.

9. The above unaudited consolidated financial results are available on the Company's website (www.gaudiumivfcentre.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board of Directors of
Gaudium IVF and Women Health Limited

Dr. Manika Khanna
Chairperson and Managing Director
DIN: 07090907

Gaudium IVF and Women Health Limited
New Delhi

SKGN ASSOCIATES LLP
For Identification Only
CHARTERED ACCOUNTANTS

Place: New Delhi
Date: November 12, 2026

Annexure B

Disclosure required pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations read with the SEBI Master Circular HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026:

a) Appointment of Senior Management Personnel:

Sr. No.	Details of events that need to be provided	Information of such event(s)
1	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment of Mr. Ravish Manchanda, National Head – Operations Expansion & Strategy, as Senior Management Personnel of the Company.
2	Date of appointment ~~/ re-appointment / cessation (as applicable) & term of appointment / re-appointment~~	Effective from November 12, 2026. Term: Not Applicable.
3	Brief profile (in case of appointment)	Mr. Ravish Manchanda holds an MBA in Health & Hospital Management from IIHMR, New Delhi. He has over 15 years of experience in IVF and fertility, hospitals and diagnostics, specializing in multi-Centre operations, P&L management, network expansion and ART compliance. Before joining the Company, he was Head – Operations Expansion & Strategy at Indira IVF Hospitals Private Limited. There he commissioned over 100 healthcare projects and earlier managed 51 IVF centers across North India. He has also held operations roles with House of Diagnostics and Febris Multispecialty Hospital.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

Annexure C

Details of the Proposed Variation

Table 1: Objects of the IPO and Proposed Variation

(₹ in Lakhs)

Sr. No.	Original objects of the IPO as stated in the Prospectus	*Amount allocated	Amount utilised as on Sept 30, 2026 (% achieved)	Amount unutilised as on Sept 30, 2026	Proposed Variation	Revised amount after variation	Revised timeline for utilisation
1	Funding capital expenditure towards establishment of New IVF Centres of the Company	5,000.00	1,348.48	3,651.52	Change / substitution of 6 of the 19 cities / locations (Table 2) and revision of the schedule and manner of establishment	5,000.00 (No change)	All 19 centres by Fiscal 2029 (indicative: 10 in FY27, 8 in FY28, 1 in FY29)
2	Repayment / pre-payment of outstanding borrowings	**1,807.37	1,807.37	Nil	No variation	1,807.37	Fully utilised
3	General corporate purposes	**1,420.82	1,137.46	283.37	No variation	1,420.82	As per Prospectus
	Total Net Proceeds	**8,228.19**	**4,293.31**	**3,934.89**		**8,228.19**	

*Allocations for Object Nos. 2 and 3 as revised with the approval of the Audit Committee and the Board on August 13, 2026 (original allocation: ₹2,000.00 Lakhs and ₹1,228.19 Lakhs respectively), on full repayment of the identified borrowings and transfer of the surplus of ₹192.63 Lakhs to general corporate purposes. Gross Proceeds of the Fresh Issue: ₹9,000.08 Lakhs.

** As per the offer document, ₹2,000.00 Lakhs was earmarked for the repayment/pre-payment, in full or in part, of certain outstanding borrowings availed by the Company. The Company has repaid borrowings aggregating ₹1,807.37 Lakhs during the period ended June 30, 2026, and no such borrowings remained outstanding as on June 30, 2026. The object has therefore been fully achieved.
Accordingly, based on the recommendation of the Audit Committee, the Board of Directors, at its meeting held on August 13, 2026, approved the reallocation of the unutilized balance of ₹192.63 Lakhs towards General Corporate Purposes to ensure the efficient deployment of IPO proceeds for the Company's operational and business requirements.

Table 2: City-wise locations of the 19 New IVF Centers:

Sr. No.	Original City as per Prospectus	Proposed Revised City
1	Delhi	Delhi – No Change
2	Noida	Noida – No Change
3	Gurgaon	Gurgaon – No Change
4	Lucknow	Lucknow – No Change

Sr. No.	Original City as per Prospectus	Proposed Revised City
5	Indore	Indore – No Change
6	Nagpur	Nagpur – No Change
7	Vizag	**Vijayawada**
8	Surat	Surat – No Change
9	Pune	Pune – No Change
10	Hyderabad	Hyderabad – No Change
11	Chennai	Chennai – No Change
12	Mumbai	Mumbai – No Change
13	Kolkata	Kolkata – No Change
14	Ahmedabad	**Nashik**
15	Cochin	**Bhubaneswar**
16	Coimbatore	**Dhanbad**
17	Jaipur	**Varanasi**
18	Guwahati	Guwahati – No Change
19	Kanpur	**Gorakhpur**

There is no alteration to the total funds earmarked towards Object No. 1 ("Funding capital expenditure towards establishment of New IVF Centers of our Company"), which remains unchanged at ₹5,000.00 Lakhs.

The Company will establish all 19 New IVF Centres by Fiscal 2029, i.e., by March 31, 2029, with an indicative target of establishing 10 centres in Fiscal 2027, 8 centres in Fiscal 2028 and 1 centre in Fiscal 2029. However, the centres may be established in such sequence and manner as may be feasible to the Company, without necessarily following the phase-wise sequence originally disclosed in the Prospectus.

Annexure-D

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Statement on deviation / variation in utilization of funds raised	
Name of listed entity	Gaudium IVF and Women Health Limited
Mode of Fund Raising	Public Issue (Initial Public Offering)
Date of Raising Funds	February 27, 2026 (date of listing of Equity Shares on BSE and NSE; Basis of Allotment finalized on February 25, 2026)
Amount Raised	₹9,000.08 Lakhs: Fresh Issue Gross Proceeds
Report filed for Quarter ended	Q2 FY 2026-27 (quarter ended September 30, 2026)
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (₹ in Lakhs)	Modified allocation, if any	Funds Utilized till September 30, 2026 (₹ in Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Funding capital expenditure towards establishment of New IVF Centres of the Company	No	5,000.00	No	1348.48	No Deviation	
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by the Company	No	2,000.00	1807.37	1,807.37	No Deviation	Refer Note No. 1
General Corporate Purposes (GCP)*	No	1,228.19	1420.82	1137.46	No Deviation	Refer Note No. 1
Net Proceeds		**8,228.19**		**4293.31**		
Issue Expenses	No	771.89	No	771.89	No Deviation	
Total		**9,000.08**		**5065.20**		

**The amount utilized for General Corporate Purposes does not exceed 25% of the Gross Proceeds of the Fresh Issue, in line with the disclosure in the Prospectus.*

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Note No. 1:

Estimated amount earmarked for repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by the Company, as per the offer document was Rs. 2000.00 Lakhs. The Company has repaid Rs. 1,807.37 Lakhs *outstanding borrowings during the period ended on June 30, 2026, and there is no such borrowing remain outstanding as on June 30, 2026, to fulfill the said object. Accordingly, having fulfilled the said object of issue, the Board of the Company, upon recommendation of the Audit Committee, at its meeting dated August 13, 2026, have approved to reallocate the balance amount of Rs 192.63 Lakhs earmarked for repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by the Company towards General Corporate Purpose to facilitate efficient deployment of the IPO proceeds for the operational and business requirements of the Company.*

The Company confirms that, post the proposed reallocation, the amount allocated towards GCP remains within the overall limit of 25% of the Gross Proceeds from the Fresh Issue as stated in the Offer Document.

The reallotment to remaining balance transferred to GCP, is not material and within permissible deviation limit of 10%. -.